Merck MRK announced that its phase III KEYLYNK-001 study, evaluating its blockbuster anti-PD-1 therapy Keytruda regimen in ...

"KEYLYNK-001 is the first positive phase 3 trial for Keytruda plus Lynparza, highlighting our commitment to research that may ...

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...

Merck hasn’t had much luck pairing cancer superstar Keytruda with PARP inhibitor Lynparza. | Merck hasn’t had much luck ...

US-based pharmaceutical company MSD has published results from a Phase III trial of a potential combination therapy for ...

Merck's ovarian cancer trial met its primary endpoint, while lymphoma trial data set the Phase 3 dose for zilovertamab ...

Merck has announced that the Phase 3 KEYLYNK-001 trial demonstrated that KEYTRUDA® (pembrolizumab) combined with chemotherapy ...

Merck announces phase 3 KEYLYNK-001 trial meets primary endpoint of PFS in patients with advanced epithelial ovarian cancer: Rahway, New Jersey Tuesday, December 10, 2024, 18:00 H ...

Merck (MRK) announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA plus chemotherapy followed by maintenance with LYNPARZA, with or ...

Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced ...

The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza (olaparib), with or without bevacizumab, as a first-line treatment for BRCA non-mutated ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYLYNK-001 trial ...